Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Nizar J. Bahlis, Meletios A. Dimopoulos, Darrell J. White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Maria Krevvata, Christopher Chiu, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Jon Ukropec, Ming Qi, Jesus San-Miguel

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Fingerprint

Dive into the research topics of 'Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences